Nasal spray vaccine plus immunotherapy shows promise in early throat cancer trial
NCT ID NCT07565740
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether a nasal spray vaccine (WSK-IM05) combined with an immunotherapy drug (tislelizumab) can safely shrink HPV-positive throat tumors before surgery. Nine adults with newly diagnosed, resectable HPV-positive oropharyngeal cancer will receive two cycles of the combination, then undergo surgery followed by standard care. The main goals are to check safety and see how well the tumors respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WSK-IM05 (nasal spray vaccine) and tislelizumab (immunotherapy drug)
What this could lead to
If it works, this could point toward a less invasive way to treat HPV-positive throat cancer by shrinking tumors before surgery and possibly reducing the need for harsh treatments afterward.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants, so results may not apply broadly. The combination may cause significant side effects, and the vaccine plus immunotherapy might not shrink tumors as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••